Increased Risk of Superficial Fungal Infections Among Psoriasis Patients Receiving Systemic Treatment: A Nationwide Retrospective Population-Based Cohort Study Authors: Ji-In Seo, Hasung Kim, Jung Kuk Lee, Hye-Jin Ahn, Ki-Heon Jeong, Min Kyung Shin Published: 2024 Dear Editor: Whether psoriasis predisposes patients to superficial fungal infection remains controversial. The immunomodulatory effects of systemic treatments, microbiota dysbiosis of the skin and nails, and immunologic disturbance of capillary units are contributing factors, while the abundance of antimicrobial peptides and fast turnover of the skin and nails are inhibitory factors1,2,3. Previous meta-analyses or large cohort studies were limited to onychomycosis or mucocutaneous candidiasis2,4,5. Therefore, we conducted this retrospective nationwide population-based cohort study to assess the incidence and risk of superficial fungal infections among patients with psoriasis receiving systemic treatment (Institutional Review Board KHUH 2020-03-091). Our study used data recorded in the Korean National Health Insurance claims database between January 2014 and December 2018. Participants aged ≥18 years who: 1) received a psoriasis diagnosis according to the International Classification of Diseases 10th Revision (ICD-10); and 2) received systemic treatment were enrolled. The psoriasis group was subdivided by treatment type: 1) biologics (tumor necrosis factor alpha [TNF-α], interleukin [IL]-12/23); 2) immunosuppressants (cyclosporine, methotrexate); and 3) acitretin (Supplementary Table 1). The control group included age- and sex-matched without dermatological diseases (ICD-10 codes L00–99) using the Korean National Health Insurance database. We determined the incidence of overall superficial fungal infections (ICD-10 codes B35–36) and individual infections (onychomycosis, tinea pedis, tinea corporis, tinea cruris, and candidiasis) per 1,000 person-years from enrollment to December 2019. The risk of superficial fungal infection was estimated using uni- and multivariate Cox proportional hazards regression models after the adjustment for age, sex, and comorbidities. Values of p≤0.05 were considered statistically significant. The incidence of superficial fungal infection was higher in the psoriasis versus control group (5.31 versus 2.45 per 1,000 person-years) (Table 1). The risk of superficial fungal infection was significantly higher in the psoriasis than control group (adjusted hazard ratio [aHR], 1.97; 95% confidence interval [CI], 1.88–2.06). When further stratified by treatment type, the risk was significantly higher for all groups than control: biologics (aHR, 1.44; 95% CI, 1.18–1.76), immunosuppressants (aHR, 1.90; 95% CI, 1.80–2.01), acitretin (aHR, 2.07; 95% CI, 1.96–2.19), TNF-α inhibitor (aHR, 1.75; 95% CI, 1.28–2.40), and IL-12/23 inhibitor (aHR, 1.33; 95% CI, 1.02–1.72). As an additional result, IL-17 inhibitor increased risk (aHR, 4.33; 95% CI, 2.51–7.47) (Supplementary Table 2). Table 1Risk of superficial fungal infection among psoriasis patients receiving systemic treatmentGroupFungal infection diagnosisTime of onset (days)Incidence rate (per 1,000 person-years)Univariable analysisMultivariable analysisNo. (%)Median (IQR)Crude HR (95% CI)p-valueaHR (95% CI)p-valuePsoriasis vs. CTRPsoriasis (total)4,669 (20.3)14.9 (24.3)5.312.01 (1.92–2.10)<0.051.97 (1.88–2.06)<0.05CTR3,732 (16.1)32.5 (36.1)2.451 [Reference]1 [Reference]BIO, IMS, ACT vs. CTRPsoriasis (BIO)99 (13.4)14.9 (23.1)4.561.54 (1.26–1.88)<0.051.44 (1.18–1.76)<0.05Psoriasis (IMS)2,332 (18.7)14.9 (23.4)4.981.88 (1.78–1.98)<0.051.90 (1.80–2.01)<0.05Psoriasis (ACT)2,238 (22.7)14.5 (25.6)5.742.19 (2.08–2.31)<0.052.07 (1.96–2.19)<0.05CTR3,732 (16.1)32.5 (36.1)2.451 [Reference]1 [Reference]Biologics vs. CTRTNF-α inhibitor40 (16.9)15.5 (29.8)5.031.99 (1.46–2.72)<0.051.75 (1.28–2.40)<0.05IL-12/23 inhibitor59 (11.8)14.9 (18.6)3.831.50 (1.16–1.94)<0.051.33 (1.02–1.72)<0.05CTR3,732 (16.1)32.5 (36.1)2.451 [Reference]1 [Reference] p-values <0.05 denote statistical significance.IQR: interquartile range, HR: hazard ratio, CI: confidence interval, aHR: adjusted hazard ratio, CTR: control, BIO: biologics, IMS: immunosuppressants, ACT: acitretin, TNF-α: tumor necrosis factor alpha, IL: interleukin. Risk of superficial fungal infection among psoriasis patients receiving systemic treatment p-values <0.05 denote statistical significance. IQR: interquartile range, HR: hazard ratio, CI: confidence interval, aHR: adjusted hazard ratio, CTR: control, BIO: biologics, IMS: immunosuppressants, ACT: acitretin, TNF-α: tumor necrosis factor alpha, IL: interleukin. In the subgroup analyses, all individual superficial fungal infections presented significantly increased risks among psoriasis patients versus controls: tinea capitis (aHR, 4.55; 95% CI, 3.39-6.11), tinea pedis (aHR, 1.76; 95% CI, 1.65–1.87), onychomycosis (aHR, 1.83; 95% CI, 1.70–1.96), tinea corporis (aHR, 2.34; 95% CI, 2.14–2.56), tinea cruris (aHR, 1.83; 95% CI, 1.59–2.12), and candidiasis (aHR, 1.18; 95% CI, 1.10-1.27) (Table 2). Table 2Subgroup analyses of association of superficial fungal infection risk with systemic treatmentGroupTinea capitisTinea pedisOnychomycosisTinea corporisTinea crurisCandidiasisaHR (95% CI)p-valueaHR (95% CI)p-valueaHR (95% CI)p-valueaHR (95% CI)p-valueaHR (95% CI)p-valueaHR (95% CI)p-valuePsoriasis vs CTRPsoriasis (Total)4.55 (3.39–6.11)<0.051.76 (1.65–1.87)<0.051.83 (1.70–1.96)<0.052.34 (2.14–2.56)<0.051.83 (1.59–2.12)<0.051.18 (1.10–1.27)<0.05CTR1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference]BIO, IMS, ACT vs. CTRPsoriasis (BIO)2.49 (0.77–8.02)0.131.47 (1.11–1.95)<0.051.33 (0.95–1.85)0.091.04 (0.64–1.68)0.891.23 (0.63–2.39)0.550.97 (0.67–1.40)0.85Psoriasis (IMS)3.42 (2.42–4.83)<0.051.53 (1.41–1.66)<0.051.71 (1.57–1.87)<0.052.23 (2.00–2.47)<0.051.95 (1.64–2.31)<0.051.22 (1.13–1.32)<0.05Psoriasis (ACT)5.73 (4.19–7.84)<0.052.00 (1.86–2.16)<0.051.96 (1.80–2.13)<0.052.51 (2.26–2.78)<0.051.75 (1.47–2.08)<0.051.13 (1.02–1.25)<0.05CTR1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference]BIO vs. CTRTNF-α inhibitor4.09 (0.96–17.47)0.061.49 (0.93–2.37)0.11.98 (1.24–3.16)<0.051.47 (0.73–2.98)0.281.53 (0.56–4.13)0.410.64 (0.31–1.36)0.25IL-12/23 inhibitor1.16 (0.16–8.62)0.891.46 (1.04–2.07)<0.051.02 (0.63–1.62)0.950.89 (0.46–1.72)0.720.99 (0.41–2.43)0.991.19 (0.78–1.83)0.42CTR1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference]1 [Reference] p-values <0.05 denote statistical significance.aHR: adjusted hazard ratio, CI: confidence interval, CTR: control, BIO: biologics, IMS: immunosuppressants, ACT: acitretin, IL: interleukin, TNF-α: tumor necrosis factor alpha. Subgroup analyses of association of superficial fungal infection risk with systemic treatment p-values <0.05 denote statistical significance. aHR: adjusted hazard ratio, CI: confidence interval, CTR: control, BIO: biologics, IMS: immunosuppressants, ACT: acitretin, IL: interleukin, TNF-α: tumor necrosis factor alpha. Our study showed an increased risk of superficial fungal infection among patients with psoriasis receiving systemic treatment regardless of treatment type. Low cellular immune function and disruption of the normal structure of the psoriatic skin can increase the fungal colonization, and fungal superantigens can prolong psoriasis3. We suggest that superficial fungal infection risk is increased in psoriasis patients. Limitations include the small number of IL-17 inhibitor group due to short period of domestic approval, lower accuracy of outcome measures by reliance on ICD-10 codes rather than diagnostic examinations, and lack of individualized analyses of methotrexate and cyclosporine. The diagnosis rate of superficial fungal infection may be higher because psoriasis patients frequently see a dermatologist. As nail deformity and skin manifestations in psoriasis resemble onychomycosis and superficial dermatophytosis, clinicians should carefully monitor superficial fungal infections in patients with psoriasis receiving systemic treatment. Footnotes FUNDING SOURCE: This work was supported by a grant from Kyung Hee University in 2022 (KHU-20220710), Republic of Korea. CONFLICTS OF INTEREST: The authors have nothing to disclose. SUPPLEMENTARY MATERIALS Supplementary Table 1 Demographic and baseline characteristics of comorbidities in psoriasis patients Supplementary Table 2 Risk of superficial fungal infection among psoriasis patients receiving IL-17 inhibitor References Associated Data Supplementary Materials Supplementary Table 1 Demographic and baseline characteristics of comorbidities in psoriasis patients Supplementary Table 2 Risk of superficial fungal infection among psoriasis patients receiving IL-17 inhibitor